{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:48:09Z","timestamp":1793908089530,"version":"4.8.0"},"reference-count":190,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["VISN7 Research Development Award"],"award-info":[{"award-number":["VISN7 Research Development Award"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK2BX005605"],"award-info":[{"award-number":["IK2BX005605"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH NIAMS","award":["5T32AR050958"],"award-info":[{"award-number":["5T32AR050958"]}]},{"DOI":"10.13039\/100012051","name":"Lupus Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015502","name":"Dialysis Clinics","doi-asserted-by":"publisher","award":["2023-10"],"award-info":[{"award-number":["2023-10"]}],"id":[{"id":"10.13039\/100015502","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006942","name":"Medical University of South Carolina","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006942","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiovascular disease (CVD) and neuropsychiatric manifestations are common in patients with Systemic Lupus Erythematosus (SLE), often sharing a vascular origin with endothelial dysfunction central to their development. The endothelium plays a critical role in regulating systemic and cerebral blood flow and influencing end-organ damage in SLE. In this review, we summarize foundational and recent studies linking vascular dysfunction to CVD and neuropsychiatric outcomes, emphasizing the roles of endothelial activation, endothelial progenitor cells, blood\u2013brain barrier dysfunction, and vascular autoantibodies. We also highlight animal models that facilitate the study of vascular and cerebral manifestations, clarifying the interconnected contributions of endothelial health to SLE-related organ damage. Finally, we discuss emerging therapeutic strategies aimed at restoring endothelial function to improve cardiovascular and neuropsychiatric outcomes in SLE.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s12265-026-10753-z","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T17:56:59Z","timestamp":1772906219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Endothelial Dysfunction: Insights into Systemic Lupus Erythematosus-associated Cardiovascular Disease and Neuropsychiatric Manifestations"],"prefix":"10.1007","volume":"19","author":[{"given":"Helen M.","family":"Butler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Elaine","family":"Zehntner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9265-9915","authenticated-orcid":false,"given":"Justin P.","family":"Van Beusecum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"10753_CR1","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677\u201386. https:\/\/doi.org\/10.1002\/art.34473.","journal-title":"Arthritis Rheum"},{"key":"10753_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-51546-1","volume":"14","author":"JY Han","year":"2024","unstructured":"Han JY, et al. Increased cardiovascular risk in Korean patients with systemic lupus erythematosus: a population-based cohort study. Sci Rep. 2024;14:1082. https:\/\/doi.org\/10.1038\/s41598-024-51546-1.","journal-title":"Sci Rep"},{"key":"10753_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2022-223035","volume":"82","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82:351\u20136. https:\/\/doi.org\/10.1136\/ard-2022-223035.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-45171-7","volume":"13","author":"J Mihailovic","year":"2023","unstructured":"Mihailovic J, et al. Worse cardiovascular and renal outcome in male SLE patients. Sci Rep. 2023;13:18628. https:\/\/doi.org\/10.1038\/s41598-023-45171-7.","journal-title":"Sci Rep"},{"key":"10753_CR5","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1136\/annrheumdis-2017-211206","volume":"76","author":"I Gergianaki","year":"2017","unstructured":"Gergianaki I, et al. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis. 2017;76:1992\u20132000. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211206.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","volume":"145","author":"S Manzi","year":"1997","unstructured":"Manzi S, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997;145:408\u201315. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a009122.","journal-title":"Am J Epidemiol"},{"key":"10753_CR7","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3899\/jrheum.101132","volume":"38","author":"JM Sabio","year":"2011","unstructured":"Sabio JM, et al. Prevalence of and factors associated with hypertension in young and old women with systemic lupus erythematosus. J Rheumatol. 2011;38:1026\u201332. https:\/\/doi.org\/10.3899\/jrheum.101132.","journal-title":"J Rheumatol"},{"key":"10753_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000454","author":"S Ajeganova","year":"2021","unstructured":"Ajeganova S, Hafstr\u00f6m I, Frosteg\u00e5rd J. Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case-control study over 10 years. Lupus Sci Med. 2021. https:\/\/doi.org\/10.1136\/lupus-2020-000454.","journal-title":"Lupus Sci Med"},{"key":"10753_CR9","first-page":"713","volume":"31","author":"L Bj\u00f6rn\u00e5dal","year":"2004","unstructured":"Bj\u00f6rn\u00e5dal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964\u201395. J Rheumatol. 2004;31:713\u20139.","journal-title":"J Rheumatol"},{"key":"10753_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001247","author":"J Yazdany","year":"2020","unstructured":"Yazdany J, et al. Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. RMD Open. 2020. https:\/\/doi.org\/10.1136\/rmdopen-2020-001247.","journal-title":"RMD Open"},{"key":"10753_CR11","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/heartjnl-2017-311214","volume":"103","author":"A Dregan","year":"2017","unstructured":"Dregan A, Chowienczyk P, Molokhia M. Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders. Heart. 2017;103:1867\u201373. https:\/\/doi.org\/10.1136\/heartjnl-2017-311214.","journal-title":"Heart"},{"key":"10753_CR12","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1002\/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i","volume":"44","author":"JM Esdaile","year":"2001","unstructured":"Esdaile JM, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331\u20137. https:\/\/doi.org\/10.1002\/1529-0131(200110)44:10%3c2331::aid-art395%3e3.0.co;2-i.","journal-title":"Arthritis Rheum"},{"key":"10753_CR13","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1002\/art.11296","volume":"48","author":"IN Bruce","year":"2003","unstructured":"Bruce IN, Urowitz MB, Gladman DD, Iba\u00f1ez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 2003;48:3159\u201367. https:\/\/doi.org\/10.1002\/art.11296.","journal-title":"Arthritis Rheum"},{"key":"10753_CR14","unstructured":"Lima DS, Sato EI, Lima VC, Miranda F Jr., Hatta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol. 2002;29:292\u20137."},{"key":"10753_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1161\/01.Cir.0000136807.78534.50","volume":"110","author":"M El-Magadmi","year":"2004","unstructured":"El-Magadmi M, et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation. 2004;110:399\u2013404. https:\/\/doi.org\/10.1161\/01.Cir.0000136807.78534.50.","journal-title":"Circulation"},{"key":"10753_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jaut.2006.09.008","volume":"27","author":"E Kiss","year":"2006","unstructured":"Kiss E, et al. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun. 2006;27:211\u20137. https:\/\/doi.org\/10.1016\/j.jaut.2006.09.008.","journal-title":"J Autoimmun"},{"key":"10753_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07574-1","volume":"7","author":"A Mak","year":"2017","unstructured":"Mak A, et al. Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression. Sci Rep. 2017;7:7320. https:\/\/doi.org\/10.1038\/s41598-017-07574-1.","journal-title":"Sci Rep"},{"key":"10753_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2020.01.028","volume":"297","author":"C Mendoza-Pinto","year":"2020","unstructured":"Mendoza-Pinto C, et al. Endothelial dysfunction and arterial stiffness in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Atherosclerosis. 2020;297:55\u201363. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.01.028.","journal-title":"Atherosclerosis"},{"key":"10753_CR19","doi-asserted-by":"publisher","unstructured":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599\u2013608. https:\/\/doi.org\/10.1002\/1529-0131(199904)42:4<599::Aid-anr2>3.0.Co;2-f.","DOI":"10.1002\/1529-0131(199904)42:4<599::Aid-anr2>3.0.Co;2-f"},{"key":"10753_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.nbd.2014.09.016","volume":"74","author":"JI Alvarez","year":"2015","unstructured":"Alvarez JI, et al. Focal disturbances in the blood-brain barrier are associated with formation of neuroinflammatory lesions. Neurobiol Dis. 2015;74:14\u201324. https:\/\/doi.org\/10.1016\/j.nbd.2014.09.016.","journal-title":"Neurobiol Dis"},{"key":"10753_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2023.103390","volume":"38","author":"T Salomonsson","year":"2023","unstructured":"Salomonsson T, et al. Abnormal cerebral hemodynamics and blood-brain barrier permeability detected with perfusion MRI in systemic lupus erythematosus patients. NeuroImage: Clinical. 2023;38:103390. https:\/\/doi.org\/10.1016\/j.nicl.2023.103390.","journal-title":"NeuroImage: Clinical"},{"key":"10753_CR22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3174\/ajnr.A5990","volume":"40","author":"JM Chi","year":"2019","unstructured":"Chi JM, et al. Alterations in blood-brain barrier permeability in patients with systemic lupus erythematosus. AJNR Am J Neuroradiol. 2019;40:470\u20137. https:\/\/doi.org\/10.3174\/ajnr.A5990.","journal-title":"AJNR Am J Neuroradiol"},{"key":"10753_CR23","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/annrheumdis-2020-218004","volume":"79","author":"L Kamintsky","year":"2020","unstructured":"Kamintsky L, et al. Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment. Ann Rheum Dis. 2020;79:1580\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218004.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000668","author":"JG Hanly","year":"2022","unstructured":"Hanly JG, et al. Role of autoantibodies and blood-brain barrier leakage in cognitive impairment in systemic lupus erythematosus. Lupus Sci Med. 2022. https:\/\/doi.org\/10.1136\/lupus-2022-000668.","journal-title":"Lupus Sci Med"},{"key":"10753_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s002960000060","volume":"20","author":"J Song","year":"2000","unstructured":"Song J, Park YB, Lee WK, Lee KH, Lee SK. Clinical associations of anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Rheumatol Int. 2000;20:1\u20137. https:\/\/doi.org\/10.1007\/s002960000060.","journal-title":"Rheumatol Int"},{"key":"10753_CR26","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1182\/blood-2006-08-044669","volume":"109","author":"OJ Florey","year":"2007","unstructured":"Florey OJ, Johns M, Esho OO, Mason JC, Haskard DO. Antiendothelial cell antibodies mediate enhanced leukocyte adhesion to cytokine-activated endothelial cells through a novel mechanism requiring cooperation between Fc\u03b3RIIa and CXCR1\/2. Blood. 2007;109:3881\u20139. https:\/\/doi.org\/10.1182\/blood-2006-08-044669.","journal-title":"Blood"},{"key":"10753_CR27","doi-asserted-by":"publisher","first-page":"R366","DOI":"10.1186\/ar1198","volume":"6","author":"F Conti","year":"2004","unstructured":"Conti F, et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res Ther. 2004;6:R366-372. https:\/\/doi.org\/10.1186\/ar1198.","journal-title":"Arthritis Res Ther"},{"key":"10753_CR28","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.tips.2016.05.012","volume":"37","author":"AD Hogan-Cann","year":"2016","unstructured":"Hogan-Cann AD, Anderson CM. Physiological roles of non-neuronal NMDA receptors. Trends Pharmacol Sci. 2016;37:750\u201367. https:\/\/doi.org\/10.1016\/j.tips.2016.05.012.","journal-title":"Trends Pharmacol Sci"},{"key":"10753_CR29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1177\/00033197221078056","volume":"73","author":"TK Ming Wang","year":"2022","unstructured":"Ming Wang TK, et al. Cardiovascular manifestations, imaging, and outcomes in systemic lupus erythematosus: an eight-year single center experience in the United States. Angiology. 2022;73:877\u201386. https:\/\/doi.org\/10.1177\/00033197221078056.","journal-title":"Angiology"},{"key":"10753_CR30","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa035611","volume":"349","author":"Y Asanuma","year":"2003","unstructured":"Asanuma Y, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2407\u201315. https:\/\/doi.org\/10.1056\/NEJMoa035611.","journal-title":"N Engl J Med"},{"key":"10753_CR31","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMoa035471","volume":"349","author":"MJ Roman","year":"2003","unstructured":"Roman MJ, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2399\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa035471.","journal-title":"N Engl J Med"},{"key":"10753_CR32","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.06.010","volume":"121","author":"JE Salmon","year":"2008","unstructured":"Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;121:S3-8. https:\/\/doi.org\/10.1016\/j.amjmed.2008.06.010.","journal-title":"Am J Med"},{"key":"10753_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000023184","volume":"99","author":"T Du","year":"2020","unstructured":"Du T, et al. Reduction in SLEDAI is associated with improved arterial stiffness in systemic lupus erythematosus. Medicine (Baltimore). 2020;99:e23184. https:\/\/doi.org\/10.1097\/md.0000000000023184.","journal-title":"Medicine (Baltimore)"},{"key":"10753_CR34","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/archinte.1976.03630090033009","volume":"136","author":"DR Budman","year":"1976","unstructured":"Budman DR, Steinberg AD. Hypertension and renal disease in systemic lupus erythematosus. Arch Intern Med. 1976;136:1003\u20137.","journal-title":"Arch Intern Med"},{"key":"10753_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"A Fanouriakis","year":"2021","unstructured":"Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80:14\u201325. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218272.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR36","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1093\/rheumatology\/keu012","volume":"53","author":"C H\u00fcbbe-Tena","year":"2014","unstructured":"H\u00fcbbe-Tena C, et al. Pulmonary hypertension in systemic lupus erythematosus: echocardiography-based definitions predict 6-year survival. Rheumatology (Oxford). 2014;53:1256\u201363. https:\/\/doi.org\/10.1093\/rheumatology\/keu012.","journal-title":"Rheumatology (Oxford)"},{"key":"10753_CR37","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1017\/s1047951121000688","volume":"31","author":"Y Lei","year":"2021","unstructured":"Lei Y, Zhang X, Feng Y, Wang J, Luo R. Risk factors of pulmonary arterial hypertension in patients with systemic lupus erythematosus. Cardiol Young. 2021;31:1619\u201324. https:\/\/doi.org\/10.1017\/s1047951121000688.","journal-title":"Cardiol Young"},{"key":"10753_CR38","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acr.23509","volume":"70","author":"JG Hanly","year":"2018","unstructured":"Hanly JG, et al. Cerebrovascular events in systemic lupus erythematosus: results from an international inception cohort study. Arthritis Care Res (Hoboken). 2018;70:1478\u201387. https:\/\/doi.org\/10.1002\/acr.23509.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10753_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2169\/internalmedicine.51.6154","volume":"51","author":"CC Chiu","year":"2012","unstructured":"Chiu CC, et al. Increased risk of ischemic stroke in patients with systemic lupus erythematosus: a nationwide population-based study. Intern Med. 2012;51:17\u201321. https:\/\/doi.org\/10.2169\/internalmedicine.51.6154.","journal-title":"Intern Med"},{"key":"10753_CR40","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1136\/annrheumdis-2016-210973","volume":"76","author":"EV Arkema","year":"2017","unstructured":"Arkema EV, Svenungsson E, Von Euler M, Sj\u00f6wall C, Simard JF. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. Ann Rheum Dis. 2017;76:1544\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210973.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR41","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.semarthrit.2018.07.012","volume":"48","author":"M Barbhaiya","year":"2019","unstructured":"Barbhaiya M, et al. Racial\/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2019;48:840\u20136. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.07.012.","journal-title":"Semin Arthritis Rheum"},{"key":"10753_CR42","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.2169\/internalmedicine.9228-21","volume":"61","author":"T Kitano","year":"2022","unstructured":"Kitano T, et al. Heterogeneity of stroke in patients with systemic lupus erythematosus. Intern Med. 2022;61:3045\u201352. https:\/\/doi.org\/10.2169\/internalmedicine.9228-21.","journal-title":"Intern Med"},{"key":"10753_CR43","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1177\/17474930231174227","volume":"18","author":"KC Chang","year":"2023","unstructured":"Chang KC, et al. Severe lupus flare is associated with a much higher risk of stroke among patients with SLE. Int J Stroke. 2023;18:957\u201364. https:\/\/doi.org\/10.1177\/17474930231174227.","journal-title":"Int J Stroke"},{"key":"10753_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1161\/01.Str.0000254476.05620.14","volume":"38","author":"J Mikdashi","year":"2007","unstructured":"Mikdashi J, Handwerger B, Langenberg P, Miller M, Kittner S. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke. 2007;38:281\u20135. https:\/\/doi.org\/10.1161\/01.Str.0000254476.05620.14.","journal-title":"Stroke"},{"key":"10753_CR45","first-page":"863","volume":"22","author":"RM Carbotte","year":"1995","unstructured":"Carbotte RM, Denburg SD, Denburg JA. Cognitive dysfunction in systemic lupus erythematosus is independent of active disease. J Rheumatol. 1995;22:863\u20137.","journal-title":"J Rheumatol"},{"key":"10753_CR46","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3899\/jrheum.160290","volume":"44","author":"CM Zhu","year":"2017","unstructured":"Zhu CM, et al. Spatial working memory impairment in patients with non-neuropsychiatric systemic lupus erythematosus: a blood-oxygen-level dependent functional magnetic resonance imaging study. J Rheumatol. 2017;44:201\u20138. https:\/\/doi.org\/10.3899\/jrheum.160290.","journal-title":"J Rheumatol"},{"key":"10753_CR47","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1002\/hbm.21158","volume":"32","author":"Y Lin","year":"2011","unstructured":"Lin Y, et al. Localization of cerebral functional deficits in patients with non-neuropsychiatric systemic lupus erythematosus. Hum Brain Mapp. 2011;32:1847\u201355. https:\/\/doi.org\/10.1002\/hbm.21158.","journal-title":"Hum Brain Mapp"},{"key":"10753_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semarthrit.2010.08.001","volume":"41","author":"A Unterman","year":"2011","unstructured":"Unterman A, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011;41:1\u201311. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.08.001.","journal-title":"Semin Arthritis Rheum"},{"key":"10753_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2024.111500","volume":"176","author":"G Markousis-Mavrogenis","year":"2024","unstructured":"Markousis-Mavrogenis G, et al. Combined brain-heart MRI identifies cardiac and white matter lesions in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome: a pilot study. Eur J Radiol. 2024;176:111500. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111500.","journal-title":"Eur J Radiol"},{"key":"10753_CR50","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.tcm.2022.02.002","volume":"33","author":"S Luo","year":"2023","unstructured":"Luo S, et al. Cardiovascular magnetic resonance imaging in myocardial involvement of systemic lupus erythematosus. Trends Cardiovasc Med. 2023;33:346\u201354. https:\/\/doi.org\/10.1016\/j.tcm.2022.02.002.","journal-title":"Trends Cardiovasc Med"},{"key":"10753_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001214","author":"D Vald\u00e9s Cabrera","year":"2024","unstructured":"Vald\u00e9s Cabrera D, et al. Effects of systemic lupus erythematosus on the brain: a systematic review of structural MRI findings and their relationships with cognitive dysfunction. Lupus Sci Med. 2024. https:\/\/doi.org\/10.1136\/lupus-2024-001214.","journal-title":"Lupus Sci Med"},{"key":"10753_CR52","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/rheumatology\/keac343","volume":"62","author":"JG Hanly","year":"2023","unstructured":"Hanly JG, et al. Resting state functional connectivity in SLE patients and association with cognitive impairment and blood-brain barrier permeability. Rheumatology (Oxford). 2023;62:685\u201395. https:\/\/doi.org\/10.1093\/rheumatology\/keac343.","journal-title":"Rheumatology (Oxford)"},{"key":"10753_CR53","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/09612033211004727","volume":"30","author":"KY Yu","year":"2021","unstructured":"Yu KY, et al. Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis. Lupus. 2021;30:1039\u201350. https:\/\/doi.org\/10.1177\/09612033211004727.","journal-title":"Lupus"},{"key":"10753_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241311118","author":"J Lee","year":"2023","unstructured":"Lee J, et al. Altered hippocampal and striatal expression of endothelial markers and VIP\/PACAP neuropeptides in a mouse model of systemic lupus erythematosus. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241311118.","journal-title":"Int J Mol Sci"},{"key":"10753_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0165-5728(03)00262-5","volume":"142","author":"A Zameer","year":"2003","unstructured":"Zameer A, Hoffman SA. Increased ICAM-1 and VCAM-1 expression in the brains of autoimmune mice. J Neuroimmunol. 2003;142:67\u201374. https:\/\/doi.org\/10.1016\/s0165-5728(03)00262-5.","journal-title":"J Neuroimmunol"},{"key":"10753_CR56","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/acr2.11744","volume":"6","author":"MK McCrorey","year":"2024","unstructured":"McCrorey MK, et al. A novel preclinical murine model of systemic lupus erythematosus-like cardiovascular disease. ACR Open Rheumatol. 2024;6:891\u20139. https:\/\/doi.org\/10.1002\/acr2.11744.","journal-title":"ACR Open Rheumatol"},{"key":"10753_CR57","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/0961203319899478","volume":"29","author":"WB Cicarini","year":"2020","unstructured":"Cicarini WB, et al. Impact of markers of endothelial injury and hypercoagulability on systemic lupus erythematosus. Lupus. 2020;29:182\u201390. https:\/\/doi.org\/10.1177\/0961203319899478.","journal-title":"Lupus"},{"key":"10753_CR58","first-page":"1307","volume":"35","author":"A Kuryliszyn-Moskal","year":"2008","unstructured":"Kuryliszyn-Moskal A, Klimiuk PA, Ciolkiewicz M, Sierakowski S. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus. J Rheumatol. 2008;35:1307\u201313.","journal-title":"J Rheumatol"},{"key":"10753_CR59","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jacc.2006.09.053","volume":"49","author":"S Yl\u00e4-Herttuala","year":"2007","unstructured":"Yl\u00e4-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol. 2007;49:1015\u201326. https:\/\/doi.org\/10.1016\/j.jacc.2006.09.053.","journal-title":"J Am Coll Cardiol"},{"key":"10753_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72020-8","volume":"10","author":"ZC Yuan","year":"2020","unstructured":"Yuan ZC, et al. Gene polymorphisms and serum levels of sVEGFR-1 in patients with systemic lupus erythematosus. Sci Rep. 2020;10:15031. https:\/\/doi.org\/10.1038\/s41598-020-72020-8.","journal-title":"Sci Rep"},{"key":"10753_CR61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00005-007-0017-7","volume":"55","author":"A Kuryliszyn-Moskal","year":"2007","unstructured":"Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Cio\u0142kiewicz M. Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities. Arch Immunol Ther Exp (Warsz). 2007;55:179\u201385. https:\/\/doi.org\/10.1007\/s00005-007-0017-7.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10753_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01487-w","volume":"24","author":"AA Mangoni","year":"2024","unstructured":"Mangoni AA, Zinellu A. The vascular endothelial growth factor as a candidate biomarker of systemic lupus erythematosus: a GRADE-assessed systematic review and meta-analysis. Clin Exp Med. 2024;24:218. https:\/\/doi.org\/10.1007\/s10238-024-01487-w.","journal-title":"Clin Exp Med"},{"key":"10753_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/biom12121884","author":"F G\u00f3mez-Bernal","year":"2022","unstructured":"G\u00f3mez-Bernal F, et al. Vascular endothelial growth factor and its soluble receptor in systemic lupus erythematosus patients. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12121884.","journal-title":"Biomolecules"},{"key":"10753_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14145133","author":"K Fischer","year":"2025","unstructured":"Fischer K, Przepiera-B\u0119dzak H, Sawicki M, Brzosko M, Brzosko M. Serum concentrations of vascular endothelial growth factor in Polish patients with systemic lupus erythematosus are associated with cardiovascular risk and autoantibody profiles. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14145133.","journal-title":"J Clin Med"},{"key":"10753_CR65","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/ard.50.7.526-c","volume":"50","author":"H Julkunen","year":"1991","unstructured":"Julkunen H, Saijonmaa O, Gr\u00f6nhagen-Riska C, Teppo AM, Fyhrquist F. Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. Ann Rheum Dis. 1991;50:526\u20137. https:\/\/doi.org\/10.1136\/ard.50.7.526-c.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR66","doi-asserted-by":"publisher","first-page":"F1477","DOI":"10.1152\/ajprenal.90713.2008","volume":"296","author":"N Dhaun","year":"2009","unstructured":"Dhaun N, et al. Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol. 2009;296:F1477-1483. https:\/\/doi.org\/10.1152\/ajprenal.90713.2008.","journal-title":"Am J Physiol Renal Physiol"},{"key":"10753_CR67","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1177\/0961203318796285","volume":"27","author":"M Hajialilo","year":"2018","unstructured":"Hajialilo M, et al. Relationship between serum vascular cell adhesion molecule-1 and endothelin-1 levels with organ involvement and disease activity in systemic lupus erythematosus patients. Lupus. 2018;27:1918\u201325. https:\/\/doi.org\/10.1177\/0961203318796285.","journal-title":"Lupus"},{"key":"10753_CR68","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000173768","volume":"16","author":"T Nakamura","year":"1993","unstructured":"Nakamura T, et al. Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB\/W F1 mice. Ren Physiol Biochem. 1993;16:233\u201343. https:\/\/doi.org\/10.1159\/000173768.","journal-title":"Ren Physiol Biochem"},{"key":"10753_CR69","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ki.1995.61","volume":"47","author":"T Nakamura","year":"1995","unstructured":"Nakamura T, Ebihara I, Tomino Y, Koide H. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int. 1995;47:481\u20139. https:\/\/doi.org\/10.1038\/ki.1995.61.","journal-title":"Kidney Int"},{"key":"10753_CR70","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/ard.54.5.361","volume":"54","author":"T Yoshio","year":"1995","unstructured":"Yoshio T, et al. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis. 1995;54:361\u20135. https:\/\/doi.org\/10.1136\/ard.54.5.361.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103399","volume":"152","author":"H Xu","year":"2025","unstructured":"Xu H, et al. Aberrant expansion of CD177(+) neutrophils promotes endothelial dysfunction in systemic lupus erythematosus via neutrophil extracellular traps. J Autoimmun. 2025;152:103399. https:\/\/doi.org\/10.1016\/j.jaut.2025.103399.","journal-title":"J Autoimmun"},{"key":"10753_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.914468","volume":"13","author":"AS Elshikha","year":"2022","unstructured":"Elshikha AS, et al. TLR7 activation accelerates cardiovascular pathology in a mouse model of lupus. Front Immunol. 2022;13:914468. https:\/\/doi.org\/10.3389\/fimmu.2022.914468.","journal-title":"Front Immunol"},{"key":"10753_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000508","volume":"3","author":"H Tyd\u00e9n","year":"2017","unstructured":"Tyd\u00e9n H, et al. Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus. RMD Open. 2017;3:e000508. https:\/\/doi.org\/10.1136\/rmdopen-2017-000508.","journal-title":"RMD Open"},{"key":"10753_CR74","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1161\/atvbaha.113.302680","volume":"34","author":"F Conti","year":"2014","unstructured":"Conti F, et al. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on \u03b22GPI-specific T cell response. Arterioscler Thromb Vasc Biol. 2014;34:661\u20138. https:\/\/doi.org\/10.1161\/atvbaha.113.302680.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10753_CR75","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/rheumatology\/keu431","volume":"54","author":"AM Cates","year":"2015","unstructured":"Cates AM, et al. Interleukin 10 hampers endothelial cell differentiation and enhances the effects of interferon \u03b1 on lupus endothelial cell progenitors. Rheumatology (Oxford). 2015;54:1114\u201323. https:\/\/doi.org\/10.1093\/rheumatology\/keu431.","journal-title":"Rheumatology (Oxford)"},{"key":"10753_CR76","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.ard.2025.04.006","volume":"84","author":"D Nikolopoulos","year":"2025","unstructured":"Nikolopoulos D, et al. Enhanced B cell and complement cascade gene signatures in patients with neuropsychiatric systemic lupus erythematosus. Ann Rheum Dis. 2025;84:1342\u201353. https:\/\/doi.org\/10.1016\/j.ard.2025.04.006.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR77","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1136\/ard-2022-223506","volume":"82","author":"D Nikolopoulos","year":"2023","unstructured":"Nikolopoulos D, et al. Microglia activation in the presence of intact blood-brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus. Ann Rheum Dis. 2023;82:646\u201357. https:\/\/doi.org\/10.1136\/ard-2022-223506.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1343805","volume":"15","author":"L Wang","year":"2024","unstructured":"Wang L, Zheng G, Wang P, Jia X. Unlocking the secrets of NPSLE: the role of dendritic cell-secreted CCL2 in blood-brain barrier disruption. Front Immunol. 2024;15:1343805. https:\/\/doi.org\/10.3389\/fimmu.2024.1343805.","journal-title":"Front Immunol"},{"key":"10753_CR79","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1161\/circulationaha.104.504340","volume":"111","author":"C Schmidt-Lucke","year":"2005","unstructured":"Schmidt-Lucke C, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111:2981\u20137. https:\/\/doi.org\/10.1161\/circulationaha.104.504340.","journal-title":"Circulation"},{"key":"10753_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03397-4","volume":"26","author":"C Rafael-Vidal","year":"2024","unstructured":"Rafael-Vidal C, et al. Novel endothelial progenitor cells populations as biomarkers of damage and remission in systemic lupus erythematosus. Arthritis Res Ther. 2024;26:170. https:\/\/doi.org\/10.1186\/s13075-024-03397-4.","journal-title":"Arthritis Res Ther"},{"key":"10753_CR81","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/ard.2006.065631","volume":"66","author":"PE Westerweel","year":"2007","unstructured":"Westerweel PE, et al. Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis. 2007;66:865\u201370. https:\/\/doi.org\/10.1136\/ard.2006.065631.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/ar2283","volume":"9","author":"JR Moonen","year":"2007","unstructured":"Moonen JR, et al. Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Res Ther. 2007;9:R84. https:\/\/doi.org\/10.1186\/ar2283.","journal-title":"Arthritis Res Ther"},{"key":"10753_CR83","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00296-009-1156-4","volume":"30","author":"XL Deng","year":"2010","unstructured":"Deng XL, Li XX, Liu XY, Sun L, Liu R. Comparative study on circulating endothelial progenitor cells in systemic lupus erythematosus patients at active stage. Rheumatol Int. 2010;30:1429\u201336. https:\/\/doi.org\/10.1007\/s00296-009-1156-4.","journal-title":"Rheumatol Int"},{"key":"10753_CR84","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1182\/blood-2007-05-089086","volume":"110","author":"MF Denny","year":"2007","unstructured":"Denny MF, et al. Interferon-\u03b1 promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood. 2007;110:2907\u201315. https:\/\/doi.org\/10.1182\/blood-2007-05-089086.","journal-title":"Blood"},{"key":"10753_CR85","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1002\/art.23035","volume":"56","author":"PY Lee","year":"2007","unstructured":"Lee PY, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2007;56:3759\u201369. https:\/\/doi.org\/10.1002\/art.23035.","journal-title":"Arthritis Rheum"},{"key":"10753_CR86","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1093\/rheumatology\/keaa875","volume":"60","author":"J Huang","year":"2021","unstructured":"Huang J, Kow NY, Lee HY, Fairhurst AM, Mak A. CD34+CD133+CD309+ circulating angiogenic cell level is reduced but positively related to hydroxychloroquine use in SLE patients-a case-control study and meta-regression analysis. Rheumatology (Oxford). 2021;60:3936\u201344. https:\/\/doi.org\/10.1093\/rheumatology\/keaa875.","journal-title":"Rheumatology (Oxford)"},{"key":"10753_CR87","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/09612033251330124","volume":"34","author":"G Silveira","year":"2025","unstructured":"Silveira G, et al. Progenitor cells and circulating endothelial cells are associated with disease activity and damage in systemic lupus erythematosus patients. Lupus. 2025;34:551\u201361. https:\/\/doi.org\/10.1177\/09612033251330124.","journal-title":"Lupus"},{"key":"10753_CR88","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/0961203309353773","volume":"19","author":"SG Thacker","year":"2010","unstructured":"Thacker SG, Duquaine D, Park J, Kaplan MJ. Lupus-prone New Zealand Black\/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus. 2010;19:288\u201399. https:\/\/doi.org\/10.1177\/0961203309353773.","journal-title":"Lupus"},{"key":"10753_CR89","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/0961203308097572","volume":"18","author":"E Robak","year":"2009","unstructured":"Robak E, et al. Circulating endothelial cells and angiogenic proteins in patients with systemic lupus erythematosus. Lupus. 2009;18:332\u201341. https:\/\/doi.org\/10.1177\/0961203308097572.","journal-title":"Lupus"},{"key":"10753_CR90","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00296-010-1377-6","volume":"31","author":"JN Ablin","year":"2011","unstructured":"Ablin JN, et al. Enhanced adhesive properties of endothelial progenitor cells (EPCs) in patients with SLE. Rheumatol Int. 2011;31:773\u20138. https:\/\/doi.org\/10.1007\/s00296-010-1377-6.","journal-title":"Rheumatol Int"},{"key":"10753_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.572876","volume":"11","author":"A Bortoluzzi","year":"2020","unstructured":"Bortoluzzi A, et al. The IMMENSE study: the interplay between iMMune and ENdothelial cells in mediating cardiovascular risk in systemic lupus erythematosus. Front Immunol. 2020;11:572876. https:\/\/doi.org\/10.3389\/fimmu.2020.572876.","journal-title":"Front Immunol"},{"key":"10753_CR92","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041422","author":"B Lacoste","year":"2025","unstructured":"Lacoste B, Prat A, Freitas-Andrade M, Gu C. The blood-brain barrier: composition, properties, and roles in brain health. Cold Spring Harb Perspect Biol. 2025. https:\/\/doi.org\/10.1101\/cshperspect.a041422.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10753_CR93","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2025-001522","author":"S Zhang","year":"2025","unstructured":"Zhang S, et al. Evaluation of MRI-based brain oxygen extraction fraction mapping in patients with systemic lupus erythematosus. Lupus Sci Med. 2025. https:\/\/doi.org\/10.1136\/lupus-2025-001522.","journal-title":"Lupus Sci Med"},{"key":"10753_CR94","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/09612033231167792","volume":"32","author":"N Koletsos","year":"2023","unstructured":"Koletsos N, et al. Depression in systemic lupus erythematosus: a manifestation of microcirculation dysfunction? Lupus. 2023;32:727\u201336. https:\/\/doi.org\/10.1177\/09612033231167792.","journal-title":"Lupus"},{"key":"10753_CR95","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/art.20980","volume":"52","author":"MD Linnik","year":"2005","unstructured":"Linnik MD, et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:1129\u201337. https:\/\/doi.org\/10.1002\/art.20980.","journal-title":"Arthritis Rheum"},{"key":"10753_CR96","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1161\/atvbaha.121.315928","volume":"41","author":"AM Pati\u00f1o-Trives","year":"2021","unstructured":"Pati\u00f1o-Trives AM, et al. Anti-dsDNA antibodies increase the cardiovascular risk in systemic lupus erythematosus promoting a distinctive immune and vascular activation. Arterioscler Thromb Vasc Biol. 2021;41:2417\u201330. https:\/\/doi.org\/10.1161\/atvbaha.121.315928.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10753_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/biom12101328","author":"K Fischer","year":"2022","unstructured":"Fischer K, et al. Anti-phosphatidylethanolamine and anti-phosphatidylserine antibodies-association with renal involvement, atherosclerosis, cardiovascular manifestations, Raynaud phenomenon and disease activity in Polish patients with systemic lupus erythematosus. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12101328.","journal-title":"Biomolecules"},{"key":"10753_CR98","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/0140-6736(90)91373-i","volume":"335","author":"MA Khamashta","year":"1990","unstructured":"Khamashta MA, et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet. 1990;335:1541\u20134. https:\/\/doi.org\/10.1016\/0140-6736(90)91373-i.","journal-title":"Lancet"},{"key":"10753_CR99","first-page":"753","volume":"9","author":"KJ Lindqvist","year":"1971","unstructured":"Lindqvist KJ, Osterland CK. Human antibodies to vascular endothelium. Clin Exp Immunol. 1971;9:753\u201360.","journal-title":"Clin Exp Immunol"},{"key":"10753_CR100","first-page":"50","volume":"40","author":"JC Tseng","year":"2007","unstructured":"Tseng JC, et al. Elevated serum anti-endothelial cell autoantibodies titer is associated with lupus nephritis in patients with systemic lupus erythematosus. J Microbiol Immunol Infect. 2007;40:50\u20135.","journal-title":"J Microbiol Immunol Infect"},{"key":"10753_CR101","first-page":"171","volume":"17","author":"C Perricone","year":"2015","unstructured":"Perricone C, et al. Neuropsychiatric manifestations associated with anti-endothelial cell antibodies in systemic lupus erythematosus. Isr Med Assoc J. 2015;17:171\u20138.","journal-title":"Isr Med Assoc J"},{"key":"10753_CR102","doi-asserted-by":"crossref","unstructured":"Carvalho D, Savage CO, Isenberg D, Pearson JD. IgG anti-endothelial cell autoantibodies from patients with systemic lupus erythematosus or systemic vasculitis stimulate the release of two endothelial cell-derived mediators, which enhance adhesion molecule expression and leukocyte adhesion in an autocrine manner. Arthritis Rheum. 1999;42:631\u201340. https:\/\/doi.org\/10.1002\/1529-0131(199904)42:4%3c631::Aid-anr5%3e3.0.Co;2-x.","DOI":"10.1002\/1529-0131(199904)42:4<631::AID-ANR5>3.0.CO;2-X"},{"key":"10753_CR103","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai9111","author":"F Shimizu","year":"2017","unstructured":"Shimizu F, et al. Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aai9111.","journal-title":"Sci Transl Med"},{"key":"10753_CR104","first-page":"1311","volume":"23","author":"T Yoshio","year":"1996","unstructured":"Yoshio T, Masuyama J, Kano S. Antiribosomal P0 protein antibodies react with the surface of human umbilical vein endothelial cells. J Rheumatol. 1996;23:1311\u20132.","journal-title":"J Rheumatol"},{"key":"10753_CR105","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00296-022-05104-5","volume":"42","author":"P Cie\u015blik","year":"2022","unstructured":"Cie\u015blik P, Semik-Grabarczyk E, Hrycek A, Holecki M. The impact of anti-endothelial cell antibodies (AECAs) on the development of blood vessel damage in patients with systemic lupus erythematosus: the preliminary study. Rheumatol Int. 2022;42:791\u2013801. https:\/\/doi.org\/10.1007\/s00296-022-05104-5.","journal-title":"Rheumatol Int"},{"key":"10753_CR106","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/01.hyp.29.2.678","volume":"29","author":"HP Luther","year":"1997","unstructured":"Luther HP, Homuth V, Wallukat G. Alpha 1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension. 1997;29:678\u201382. https:\/\/doi.org\/10.1161\/01.hyp.29.2.678.","journal-title":"Hypertension"},{"key":"10753_CR107","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1291\/hypres.25.641","volume":"25","author":"YH Liao","year":"2002","unstructured":"Liao YH, et al. Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res. 2002;25:641\u20136. https:\/\/doi.org\/10.1291\/hypres.25.641.","journal-title":"Hypertens Res"},{"key":"10753_CR108","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/ijcp.12242","volume":"67","author":"J Xiong","year":"2013","unstructured":"Xiong J, Liang Y, Yang H, Zhu F, Wang Y. The role of angiotensin II type 1 receptor-activating antibodies in patients with lupus nephritis. Int J Clin Pract. 2013;67:1066\u20137. https:\/\/doi.org\/10.1111\/ijcp.12242.","journal-title":"Int J Clin Pract"},{"key":"10753_CR109","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/ard.2010.135772","volume":"70","author":"G Riemekasten","year":"2011","unstructured":"Riemekasten G, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011;70:530\u20136. https:\/\/doi.org\/10.1136\/ard.2010.135772.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/ar4457","volume":"16","author":"A Kill","year":"2014","unstructured":"Kill A, et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther. 2014;16:R29. https:\/\/doi.org\/10.1186\/ar4457.","journal-title":"Arthritis Res Ther"},{"key":"10753_CR111","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1002\/art.39212","volume":"67","author":"L Guo","year":"2015","unstructured":"Guo L, et al. Anti-endothelin receptor type A autoantibodies in systemic lupus erythematosus-associated pulmonary arterial hypertension. Arthritis Rheumatol. 2015;67:2394\u2013402. https:\/\/doi.org\/10.1002\/art.39212.","journal-title":"Arthritis Rheumatol"},{"key":"10753_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1157149","volume":"14","author":"C Cocco","year":"2023","unstructured":"Cocco C, et al. Brain-reactive autoantibodies in neuropsychiatric systemic lupus erythematosus. Front Immunol. 2023;14:1157149. https:\/\/doi.org\/10.3389\/fimmu.2023.1157149.","journal-title":"Front Immunol"},{"key":"10753_CR113","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7430780","volume":"2019","author":"J Sun","year":"2019","unstructured":"Sun J, et al. Anti-GAPDH autoantibody is associated with increased disease activity and intracranial pressure in systemic lupus erythematosus. J Immunol Res. 2019;2019:7430780. https:\/\/doi.org\/10.1155\/2019\/7430780.","journal-title":"J Immunol Res"},{"key":"10753_CR114","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/art.22031","volume":"54","author":"L Lapteva","year":"2006","unstructured":"Lapteva L, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2505\u201314. https:\/\/doi.org\/10.1002\/art.22031.","journal-title":"Arthritis Rheum"},{"key":"10753_CR115","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.it.2009.06.003","volume":"30","author":"WH Reeves","year":"2009","unstructured":"Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009;30:455\u201364. https:\/\/doi.org\/10.1016\/j.it.2009.06.003.","journal-title":"Trends Immunol"},{"key":"10753_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/s12993-023-00205-y","volume":"19","author":"Y Yun","year":"2023","unstructured":"Yun Y, et al. Pristane induced lupus mice as a model for neuropsychiatric lupus (NPSLE). Behav Brain Funct. 2023;19:3. https:\/\/doi.org\/10.1186\/s12993-023-00205-y.","journal-title":"Behav Brain Funct"},{"key":"10753_CR117","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxae099","author":"TE Karnopp","year":"2025","unstructured":"Karnopp TE, et al. The role of vitamin D: a promising pathway to combat neuropsychiatric lupus disorders. Clin Exp Immunol. 2025. https:\/\/doi.org\/10.1093\/cei\/uxae099.","journal-title":"Clin Exp Immunol"},{"key":"10753_CR118","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/art.38298","volume":"66","author":"M Yokogawa","year":"2014","unstructured":"Yokogawa M, et al. Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic lupus erythematosus. Arthritis Rheumatol. 2014;66:694\u2013706. https:\/\/doi.org\/10.1002\/art.38298.","journal-title":"Arthritis Rheumatol"},{"key":"10753_CR119","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1242\/dmm.027409","volume":"10","author":"MG Hasham","year":"2017","unstructured":"Hasham MG, et al. Systemic autoimmunity induced by the TLR7\/8 agonist Resiquimod causes myocarditis and dilated cardiomyopathy in a new mouse model of autoimmune heart disease. Dis Model Mech. 2017;10:259\u201370. https:\/\/doi.org\/10.1242\/dmm.027409.","journal-title":"Dis Model Mech"},{"key":"10753_CR120","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.040725","author":"N Baxan","year":"2019","unstructured":"Baxan N, et al. Characterization of acute TLR-7 agonist-induced hemorrhagic myocarditis in mice by multiparametric quantitative cardiac magnetic resonance imaging. Dis Model Mech. 2019. https:\/\/doi.org\/10.1242\/dmm.040725.","journal-title":"Dis Model Mech"},{"key":"10753_CR121","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1001\/jama.1966.03100040091025","volume":"195","author":"EL Dubois","year":"1966","unstructured":"Dubois EL, Horowitz RE, Demopoulos HB, Teplitz R. NZB\/NZW mice as a model of systemic lupus erythematosus. JAMA. 1966;195:285\u20139.","journal-title":"JAMA"},{"key":"10753_CR122","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/197197a0","volume":"197","author":"BJ Helyer","year":"1963","unstructured":"Helyer BJ, Howie JB. Renal disease associated with positive lupus erythematosus tests in a cross-bred strain of mice. Nature. 1963;197:197. https:\/\/doi.org\/10.1038\/197197a0.","journal-title":"Nature"},{"key":"10753_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1182193","volume":"10","author":"R B\u00f6hme","year":"2023","unstructured":"B\u00f6hme R, et al. Cardiovascular changes in the NZB\/W F1 mouse model of lupus nephritis. Front Cardiovasc Med. 2023;10:1182193. https:\/\/doi.org\/10.3389\/fcvm.2023.1182193.","journal-title":"Front Cardiovasc Med"},{"key":"10753_CR124","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.4049\/jimmunol.161.12.6999","volume":"161","author":"L Gu","year":"1998","unstructured":"Gu L, et al. Genetic determinants of autoimmune disease and coronary vasculitis in the MRL-lpr\/lpr mouse model of systemic lupus erythematosus. J Immunol. 1998;161:6999\u20137006.","journal-title":"J Immunol"},{"key":"10753_CR125","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.biopsych.2004.11.037","volume":"57","author":"B Sakic","year":"2005","unstructured":"Sakic B, Hanna SE, Millward JM. Behavioral heterogeneity in an animal model of neuropsychiatric lupus. Biol Psychiatry. 2005;57:679\u201387. https:\/\/doi.org\/10.1016\/j.biopsych.2004.11.037.","journal-title":"Biol Psychiatry"},{"key":"10753_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2024.1446836","volume":"15","author":"H Kim","year":"2024","unstructured":"Kim H, Massett MP. Beneficial effects of rapamycin on endothelial function in systemic lupus erythematosus. Front Physiol. 2024;15:1446836. https:\/\/doi.org\/10.3389\/fphys.2024.1446836.","journal-title":"Front Physiol"},{"key":"10753_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052291","author":"P Marczynski","year":"2021","unstructured":"Marczynski P, et al. Vascular inflammation and dysfunction in lupus-prone mice-IL-6 as mediator of disease initiation. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22052291.","journal-title":"Int J Mol Sci"},{"key":"10753_CR128","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12974-015-0423-4","volume":"12","author":"AD Stock","year":"2015","unstructured":"Stock AD, et al. Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL\/lpr mice. J Neuroinflammation. 2015;12:205. https:\/\/doi.org\/10.1186\/s12974-015-0423-4.","journal-title":"J Neuroinflammation"},{"key":"10753_CR129","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jneuroim.2009.10.008","volume":"218","author":"S Williams","year":"2010","unstructured":"Williams S, Sakic B, Hoffman SA. Circulating brain-reactive autoantibodies and behavioral deficits in the MRL model of CNS lupus. J Neuroimmunol. 2010;218:73\u201382. https:\/\/doi.org\/10.1016\/j.jneuroim.2009.10.008.","journal-title":"J Neuroimmunol"},{"key":"10753_CR130","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jneuroim.2010.07.020","volume":"229","author":"HX Gao","year":"2010","unstructured":"Gao HX, Sanders E, Tieng AT, Putterman C. Sex and autoantibody titers determine the development of neuropsychiatric manifestations in lupus-prone mice. J Neuroimmunol. 2010;229:112\u201322. https:\/\/doi.org\/10.1016\/j.jneuroim.2010.07.020.","journal-title":"J Neuroimmunol"},{"key":"10753_CR131","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/0031-9384(93)90319-b","volume":"54","author":"B Saki\u0107","year":"1993","unstructured":"Saki\u0107 B, Szechtman H, Denburg S, Carbotte R, Denburg JA. Brain-reactive antibodies and behavior of autoimmune MRL-lpr mice. Physiol Behav. 1993;54:1025\u20139. https:\/\/doi.org\/10.1016\/0031-9384(93)90319-b.","journal-title":"Physiol Behav"},{"key":"10753_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03085-9","volume":"21","author":"J Reynolds","year":"2024","unstructured":"Reynolds J, et al. Constitutive knockout of interleukin-6 ameliorates memory deficits and entorhinal astrocytosis in the MRL\/lpr mouse model of neuropsychiatric lupus. J Neuroinflammation. 2024;21:89. https:\/\/doi.org\/10.1186\/s12974-024-03085-9.","journal-title":"J Neuroinflammation"},{"key":"10753_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0537-3","volume":"13","author":"J Wen","year":"2016","unstructured":"Wen J, et al. B cell and\/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus. J Neuroinflammation. 2016;13:73. https:\/\/doi.org\/10.1186\/s12974-016-0537-3.","journal-title":"J Neuroinflammation"},{"key":"10753_CR134","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0006-8993(90)91737-2","volume":"532","author":"GF Sherman","year":"1990","unstructured":"Sherman GF, Morrison L, Rosen GD, Behan PO, Galaburda AM. Brain abnormalities in immune defective mice. Brain Res. 1990;532:25\u201333. https:\/\/doi.org\/10.1016\/0006-8993(90)91737-2.","journal-title":"Brain Res"},{"key":"10753_CR135","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.bbi.2025.04.017","volume":"128","author":"A Kwun","year":"2025","unstructured":"Kwun A, et al. Sustained NPSLE-like phenotype in the absence of systemic lupus-like disease in TLR7-deficient B6.Nba2 mice. Brain Behav Immun. 2025;128:352\u201361. https:\/\/doi.org\/10.1016\/j.bbi.2025.04.017.","journal-title":"Brain Behav Immun"},{"key":"10753_CR136","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/aps.2015.91","volume":"36","author":"YW Wu","year":"2015","unstructured":"Wu YW, Tang W, Zuo JP. Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol Sin. 2015;36:1395\u2013407. https:\/\/doi.org\/10.1038\/aps.2015.91.","journal-title":"Acta Pharmacol Sin"},{"key":"10753_CR137","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.carrev.2009.11.001","volume":"12","author":"M Chyrchel","year":"2011","unstructured":"Chyrchel M, et al. Effects of short-term anti-inflammatory therapy on endothelial function in patients with non-ST-segment elevation acute coronary syndrome. Cardiovasc Revasc Med. 2011;12:2\u20139. https:\/\/doi.org\/10.1016\/j.carrev.2009.11.001.","journal-title":"Cardiovasc Revasc Med"},{"key":"10753_CR138","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1136\/ard.2003.018333","volume":"63","author":"S Van Doornum","year":"2004","unstructured":"Van Doornum S, McColl G, Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:1571\u20135. https:\/\/doi.org\/10.1136\/ard.2003.018333.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR139","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jacc.2004.11.006","volume":"45","author":"F Hermann","year":"2005","unstructured":"Hermann F, et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol. 2005;45:461\u20134. https:\/\/doi.org\/10.1016\/j.jacc.2004.11.006.","journal-title":"J Am Coll Cardiol"},{"key":"10753_CR140","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/rheumatology\/kem186","volume":"46","author":"GA Ferreira","year":"2007","unstructured":"Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford). 2007;46:1560\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/kem186.","journal-title":"Rheumatology (Oxford)"},{"key":"10753_CR141","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2015.08.030","volume":"243","author":"HH Yu","year":"2015","unstructured":"Yu HH, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study. Atherosclerosis. 2015;243:11\u20138. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.08.030.","journal-title":"Atherosclerosis"},{"key":"10753_CR142","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2015.05.022","volume":"241","author":"A Sahebkar","year":"2015","unstructured":"Sahebkar A, et al. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis. 2015;241:433\u201342. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.05.022.","journal-title":"Atherosclerosis"},{"key":"10753_CR143","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.metabol.2015.08.002","volume":"64","author":"A Sahebkar","year":"2015","unstructured":"Sahebkar A, Ponziani MC, Goitre I, Bo S. Does statin therapy reduce plasma VEGF levels in humans? A systematic review and meta-analysis of randomized controlled trials. Metabolism. 2015;64:1466\u201376. https:\/\/doi.org\/10.1016\/j.metabol.2015.08.002.","journal-title":"Metabolism"},{"key":"10753_CR144","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5114\/aoms.2019.90271","volume":"18","author":"A Mazurek","year":"2022","unstructured":"Mazurek A, et al. Influence of statin therapy on antiphospholipid antibodies and endothelial dysfunction in young patients with coronary artery disease and systemic lupus erythematosus. Arch Med Sci. 2022;18:18\u201324. https:\/\/doi.org\/10.5114\/aoms.2019.90271.","journal-title":"Arch Med Sci"},{"key":"10753_CR145","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1002\/1529-0131(200112)44:12<2870::aid-art475>3.0.co;2-y","volume":"44","author":"PL Meroni","year":"2001","unstructured":"Meroni PL, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2001;44:2870\u20138. https:\/\/doi.org\/10.1002\/1529-0131(200112)44:12%3c2870::aid-art475%3e3.0.co;2-y.","journal-title":"Arthritis Rheum"},{"key":"10753_CR146","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1161\/circulationaha.107.734384","volume":"117","author":"AJ Flammer","year":"2008","unstructured":"Flammer AJ, et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation. 2008;117:2262\u20139. https:\/\/doi.org\/10.1161\/circulationaha.107.734384.","journal-title":"Circulation"},{"key":"10753_CR147","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/rhu.0000000000001869","volume":"28","author":"ACD Oliveira","year":"2022","unstructured":"Oliveira ACD, Arismendi MI, Machado LSG, Sato EI. Ramipril improves endothelial function and increases the number of endothelial progenitor cells in patients with systemic lupus erythematosus. J Clin Rheumatol. 2022;28:349\u201353. https:\/\/doi.org\/10.1097\/rhu.0000000000001869.","journal-title":"J Clin Rheumatol"},{"key":"10753_CR148","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/vhrm.S133921","volume":"14","author":"M Correale","year":"2018","unstructured":"Correale M, et al. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? Vasc Health Risk Manag. 2018;14:253\u201364. https:\/\/doi.org\/10.2147\/vhrm.S133921.","journal-title":"Vasc Health Risk Manag"},{"key":"10753_CR149","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/annrheumdis-2019-216274","volume":"79","author":"M Kuwana","year":"2020","unstructured":"Kuwana M, Blair C, Takahashi T, Langley J, Coghlan JG. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Ann Rheum Dis. 2020;79:626\u201334. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216274.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR150","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/s0140-6736(22)02034-7","volume":"400","author":"MP Schlaich","year":"2022","unstructured":"Schlaich MP, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400:1927\u201337. https:\/\/doi.org\/10.1016\/s0140-6736(22)02034-7.","journal-title":"Lancet"},{"key":"10753_CR151","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jacc.2023.10.045","volume":"83","author":"E Gr\u00fcnig","year":"2024","unstructured":"Gr\u00fcnig E, et al. Randomized trial of macitentan\/tadalafil single-tablet combination therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2024;83:473\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.045.","journal-title":"J Am Coll Cardiol"},{"key":"10753_CR152","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000681","author":"S Fasano","year":"2022","unstructured":"Fasano S, et al. Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus. Lupus Sci Med. 2022. https:\/\/doi.org\/10.1136\/lupus-2022-000681.","journal-title":"Lupus Sci Med"},{"key":"10753_CR153","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1161\/hypertensionaha.114.03587","volume":"64","author":"M G\u00f3mez-Guzm\u00e1n","year":"2014","unstructured":"G\u00f3mez-Guzm\u00e1n M, et al. Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus. Hypertension. 2014;64:330\u20137. https:\/\/doi.org\/10.1161\/hypertensionaha.114.03587.","journal-title":"Hypertension"},{"key":"10753_CR154","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1136\/ard.2009.120329","volume":"69","author":"H Amital","year":"2010","unstructured":"Amital H, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis. 2010;69:1155\u20137. https:\/\/doi.org\/10.1136\/ard.2009.120329.","journal-title":"Ann Rheum Dis"},{"key":"10753_CR155","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6802562","volume":"2020","author":"Z Huang","year":"2020","unstructured":"Huang Z, et al. Vitamin D (1,25-(OH)(2)D(3)) improves endothelial progenitor cells function via enhanced NO secretion in systemic lupus erythematosus. Cardiol Res Pract. 2020;2020:6802562. https:\/\/doi.org\/10.1155\/2020\/6802562.","journal-title":"Cardiol Res Pract"},{"key":"10753_CR156","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/rheumatology\/keae453","volume":"64","author":"V Orefice","year":"2025","unstructured":"Orefice V, et al. Caffeine improves systemic lupus erythematosus endothelial dysfunction by promoting endothelial progenitor cells survival. Rheumatology (Oxford). 2025;64:1886\u201393. https:\/\/doi.org\/10.1093\/rheumatology\/keae453.","journal-title":"Rheumatology (Oxford)"},{"key":"10753_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00929","volume":"11","author":"Y Yan","year":"2020","unstructured":"Yan Y, et al. Coptisine alleviates pristane-induced lupus-like disease and associated kidney and cardiovascular complications in mice. Front Pharmacol. 2020;11:929. https:\/\/doi.org\/10.3389\/fphar.2020.00929.","journal-title":"Front Pharmacol"},{"key":"10753_CR158","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2147\/ndt.S359698","volume":"18","author":"X Wang","year":"2022","unstructured":"Wang X, et al. Brain-reactive antibodies are potential biomarkers for evaluating therapeutic efficacy in NPSLE patients. Neuropsychiatr Dis Treat. 2022;18:1329\u201340. https:\/\/doi.org\/10.2147\/ndt.S359698.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10753_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2022.148203","volume":"1801","author":"Y Fan","year":"2023","unstructured":"Fan Y, et al. Small molecule compound K-7174 attenuates neuropsychiatric manifestations in lupus-prone mice. Brain Res. 2023;1801:148203. https:\/\/doi.org\/10.1016\/j.brainres.2022.148203.","journal-title":"Brain Res"},{"key":"10753_CR160","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.bbi.2018.03.009","volume":"70","author":"D Shi","year":"2018","unstructured":"Shi D, et al. FTY720 attenuates behavioral deficits in a murine model of systemic lupus erythematosus. Brain Behav Immun. 2018;70:293\u2013304. https:\/\/doi.org\/10.1016\/j.bbi.2018.03.009.","journal-title":"Brain Behav Immun"},{"key":"10753_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02189","volume":"9","author":"EV Mike","year":"2018","unstructured":"Mike EV, et al. Neuropsychiatric systemic lupus erythematosus is dependent on sphingosine-1-phosphate signaling. Front Immunol. 2018;9:2189. https:\/\/doi.org\/10.3389\/fimmu.2018.02189.","journal-title":"Front Immunol"},{"key":"10753_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/nu17111820","author":"G Maalouly","year":"2025","unstructured":"Maalouly G, et al. Cinnamomum cassia alleviates neuropsychiatric lupus in a murine experimental model. Nutrients. 2025. https:\/\/doi.org\/10.3390\/nu17111820.","journal-title":"Nutrients"},{"key":"10753_CR163","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1084\/jem.20180776","volume":"215","author":"J Nestor","year":"2018","unstructured":"Nestor J, et al. Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors. J Exp Med. 2018;215:2554\u201366. https:\/\/doi.org\/10.1084\/jem.20180776.","journal-title":"J Exp Med"},{"key":"10753_CR164","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s00296-024-05667-5","volume":"44","author":"D Nikolopoulos","year":"2024","unstructured":"Nikolopoulos D, Cetrez N, Lindblom J, Parodis I. Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials. Rheumatol Int. 2024;44:1679\u201389. https:\/\/doi.org\/10.1007\/s00296-024-05667-5.","journal-title":"Rheumatol Int"},{"key":"10753_CR165","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14734","volume":"9","author":"DM McClung","year":"2021","unstructured":"McClung DM, Kalusche WJ, Jones KE, Ryan MJ, Taylor EB. Hypertension and endothelial dysfunction in the pristane model of systemic lupus erythematosus. Physiol Rep. 2021;9:e14734. https:\/\/doi.org\/10.14814\/phy2.14734.","journal-title":"Physiol Rep"},{"key":"10753_CR166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217190","volume":"14","author":"J Luciano-Jaramillo","year":"2019","unstructured":"Luciano-Jaramillo J, et al. Downregulation of hippocampal NR2A\/2B subunits related to cognitive impairment in a pristane-induced lupus BALB\/c mice. PLoS ONE. 2019;14:e0217190. https:\/\/doi.org\/10.1371\/journal.pone.0217190.","journal-title":"PLoS ONE"},{"key":"10753_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252313080","author":"D Gonz\u00e1lez-Inostroz","year":"2024","unstructured":"Gonz\u00e1lez-Inostroz D, et al. The association of anti-Sm with osteopontin related to cognitive impairment in a pristane-induced lupus BALB\/c mice model. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms252313080.","journal-title":"Int J Mol Sci"},{"key":"10753_CR168","doi-asserted-by":"publisher","first-page":"19854","DOI":"10.1073\/pnas.0608397104","volume":"103","author":"C Kowal","year":"2006","unstructured":"Kowal C, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A. 2006;103:19854\u20139. https:\/\/doi.org\/10.1073\/pnas.0608397104.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10753_CR169","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-90","volume":"11","author":"S Kivity","year":"2013","unstructured":"Kivity S, et al. 16\/6-idiotype expressing antibodies induce brain inflammation and cognitive impairment in mice: the mosaic of central nervous system involvement in lupus. BMC Med. 2013;11:90. https:\/\/doi.org\/10.1186\/1741-7015-11-90.","journal-title":"BMC Med"},{"key":"10753_CR170","doi-asserted-by":"publisher","unstructured":"Ryan MJ, McLemore GR Jr. Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol. 2007;292:R736-742. https:\/\/doi.org\/10.1152\/ajpregu.00168.2006.","DOI":"10.1152\/ajpregu.00168.2006"},{"key":"10753_CR171","doi-asserted-by":"publisher","first-page":"H1331","DOI":"10.1152\/ajpheart.00286.2022","volume":"323","author":"S Chaudhari","year":"2022","unstructured":"Chaudhari S, et al. Renal TLR-7\/TNF-\u03b1 pathway as a potential female-specific mechanism in the pathogenesis of autoimmune-induced hypertension. Am J Physiol Heart Circ Physiol. 2022;323:H1331-h1342. https:\/\/doi.org\/10.1152\/ajpheart.00286.2022.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10753_CR172","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.116.005394","author":"EB Taylor","year":"2017","unstructured":"Taylor EB, Ryan MJ. Immunosuppression with mycophenolate mofetil attenuates hypertension in an experimental model of autoimmune disease. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/jaha.116.005394.","journal-title":"J Am Heart Assoc"},{"key":"10753_CR173","doi-asserted-by":"publisher","first-page":"10005","DOI":"10.1096\/fj.201900545RR","volume":"33","author":"M Toral","year":"2019","unstructured":"Toral M, et al. Lactobacillus fermentum CECT5716: a novel alternative for the prevention of vascular disorders in a mouse model of systemic lupus erythematosus. FASEB J. 2019;33:10005\u201318. https:\/\/doi.org\/10.1096\/fj.201900545RR.","journal-title":"FASEB J"},{"key":"10753_CR174","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1037\/0735-7044.110.3.492","volume":"110","author":"LM Schrott","year":"1996","unstructured":"Schrott LM, Crnic LS. Increased anxiety behaviors in autoimmune mice. Behav Neurosci. 1996;110:492\u2013502. https:\/\/doi.org\/10.1037\/0735-7044.110.3.492.","journal-title":"Behav Neurosci"},{"key":"10753_CR175","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/0006-8993(91)91192-4","volume":"562","author":"VH Denenberg","year":"1991","unstructured":"Denenberg VH, Sherman GF, Schrott LM, Rosen GD, Galaburda AM. Spatial learning, discrimination learning, paw preference and neocortical ectopias in two autoimmune strains of mice. Brain Res. 1991;562:98\u2013104. https:\/\/doi.org\/10.1016\/0006-8993(91)91192-4.","journal-title":"Brain Res"},{"key":"10753_CR176","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/art.1780370617","volume":"37","author":"CM Vogelweid","year":"1994","unstructured":"Vogelweid CM, Wright DC, Johnson JC, Hewett JE, Walker SE. Evaluation of memory, learning ability, and clinical neurologic function in pathogen-free mice with systemic lupus erythematosus. Arthritis Rheum. 1994;37:889\u201397. https:\/\/doi.org\/10.1002\/art.1780370617.","journal-title":"Arthritis Rheum"},{"key":"10753_CR177","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1095034","volume":"14","author":"H Shi","year":"2023","unstructured":"Shi H, et al. Perivascular adipose tissue promotes vascular dysfunction in murine lupus. Front Immunol. 2023;14:1095034. https:\/\/doi.org\/10.3389\/fimmu.2023.1095034.","journal-title":"Front Immunol"},{"key":"10753_CR178","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s0361-9230(97)00107-x","volume":"44","author":"B Saki\u0107","year":"1997","unstructured":"Saki\u0107 B, et al. Reduced preference for sucrose in autoimmune mice: a possible role of interleukin-6. Brain Res Bull. 1997;44:155\u201365. https:\/\/doi.org\/10.1016\/s0361-9230(97)00107-x.","journal-title":"Brain Res Bull"},{"key":"10753_CR179","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s0166-4328(02)00276-0","volume":"140","author":"DA Ballok","year":"2003","unstructured":"Ballok DA, Szechtman H, Sakic B. Taste responsiveness and diet preference in autoimmune MRL mice. Behav Brain Res. 2003;140:119\u201330. https:\/\/doi.org\/10.1016\/s0166-4328(02)00276-0.","journal-title":"Behav Brain Res"},{"key":"10753_CR180","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/s0361-9230(96)00190-6","volume":"41","author":"B Saki\u0107","year":"1996","unstructured":"Saki\u0107 B, Denburg JA, Denburg SD, Szechtman H. Blunted sensitivity to sucrose in autoimmune MRL-lpr mice: a curve-shift study. Brain Res Bull. 1996;41:305\u201311. https:\/\/doi.org\/10.1016\/s0361-9230(96)00190-6.","journal-title":"Brain Res Bull"},{"key":"10753_CR181","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bbr.2005.07.030","volume":"166","author":"KK Anderson","year":"2006","unstructured":"Anderson KK, Ballok DA, Prasad N, Szechtman H, Sakic B. Impaired response to amphetamine and neuronal degeneration in the nucleus accumbens of autoimmune MRL-lpr mice. Behav Brain Res. 2006;166:32\u20138. https:\/\/doi.org\/10.1016\/j.bbr.2005.07.030.","journal-title":"Behav Brain Res"},{"key":"10753_CR182","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0889-1591(92)90048-s","volume":"6","author":"B Saki\u0107","year":"1992","unstructured":"Saki\u0107 B, et al. A behavioral profile of autoimmune lupus-prone MRL mice. Brain Behav Immun. 1992;6:265\u201385. https:\/\/doi.org\/10.1016\/0889-1591(92)90048-s.","journal-title":"Brain Behav Immun"},{"key":"10753_CR183","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/0031-9384(94)90309-3","volume":"56","author":"B Saki\u0107","year":"1994","unstructured":"Saki\u0107 B, et al. Disturbed emotionality in autoimmune MRL-lpr mice. Physiol Behav. 1994;56:609\u201317. https:\/\/doi.org\/10.1016\/0031-9384(94)90309-3.","journal-title":"Physiol Behav"},{"key":"10753_CR184","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jneuroim.2008.11.009","volume":"207","author":"HX Gao","year":"2009","unstructured":"Gao HX, et al. Depression is an early disease manifestation in lupus-prone MRL\/lpr mice. J Neuroimmunol. 2009;207:45\u201356. https:\/\/doi.org\/10.1016\/j.jneuroim.2008.11.009.","journal-title":"J Neuroimmunol"},{"key":"10753_CR185","doi-asserted-by":"publisher","first-page":"15150","DOI":"10.3390\/ijms160715150","volume":"16","author":"Y Li","year":"2015","unstructured":"Li Y, et al. Behavioral deficits are accompanied by immunological and neurochemical changes in a mouse model for neuropsychiatric lupus (NP-SLE). Int J Mol Sci. 2015;16:15150\u201371. https:\/\/doi.org\/10.3390\/ijms160715150.","journal-title":"Int J Mol Sci"},{"key":"10753_CR186","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/096120339700600302","volume":"6","author":"H Szechtman","year":"1997","unstructured":"Szechtman H, Saki\u0107 B, Denburg JA. Behaviour of MRL mice: an animal model of disturbed behaviour in systemic autoimmune disease. Lupus. 1997;6:223\u20139. https:\/\/doi.org\/10.1177\/096120339700600302.","journal-title":"Lupus"},{"key":"10753_CR187","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.bbi.2021.02.010","volume":"94","author":"K Browne","year":"2021","unstructured":"Browne K, et al. Lupus-prone B6.Nba2 male and female mice display anti-DWEYS reactivity and a neuropsychiatric phenotype. Brain Behav Immun. 2021;94:175\u201384. https:\/\/doi.org\/10.1016\/j.bbi.2021.02.010.","journal-title":"Brain Behav Immun"},{"key":"10753_CR188","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1370254","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, et al. Autoimmune and neuropsychiatric phenotypes in a Mecp2 transgenic mouse model on C57BL\/6 background. Front Immunol. 2024;15:1370254. https:\/\/doi.org\/10.3389\/fimmu.2024.1370254.","journal-title":"Front Immunol"},{"key":"10753_CR189","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.22409","author":"C Villani","year":"2016","unstructured":"Villani C, et al. Lovastatin fails to improve motor performance and survival in methyl-CpG-binding protein2-null mice. Elife. 2016. https:\/\/doi.org\/10.7554\/eLife.22409.","journal-title":"Elife"},{"key":"10753_CR190","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaut.2018.08.005","volume":"96","author":"EV Mike","year":"2019","unstructured":"Mike EV, et al. Lipocalin-2 is a pathogenic determinant and biomarker of neuropsychiatric lupus. J Autoimmun. 2019;96:59\u201373. https:\/\/doi.org\/10.1016\/j.jaut.2018.08.005.","journal-title":"J Autoimmun"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10753-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-026-10753-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10753-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T17:57:03Z","timestamp":1772906223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-026-10753-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":190,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10753"],"URL":"https:\/\/doi.org\/10.1007\/s12265-026-10753-z","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest, financial or otherwise.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"36"}}